1
|
Kita K, Burdowski A. Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management. World J Gastroenterol 2024; 30:1780-1790. [PMID: 38659489 PMCID: PMC11036503 DOI: 10.3748/wjg.v30.i13.1780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Revised: 02/08/2024] [Accepted: 03/19/2024] [Indexed: 04/03/2024] Open
Abstract
Colorectal cancer (CRC) has remained the second and the third leading cause of cancer-related death worldwide and in the United States, respectively. Although significant improvement in overall survival has been achieved, death in adult populations under the age of 55 appears to have increased in the past decades. Although new classes of therapeutic strategies such as immunotherapy have emerged, their application is very limited in CRC so far. Microtubule (MT) inhibitors such as taxanes, are not generally successful in CRC. There may be some way to make MT inhibitors work effectively in CRC. One potential advantage that we can take to treat CRC may be the combination of optical techniques coupled to an endoscope or other fiber optics-based devices. A combination of optical devices and photo-activatable drugs may allow us to locally target advanced CRC cells with highly potent MT-targeting drugs. In this Editorial review, we would like to discuss the potential of optogenetic approaches in CRC management.
Collapse
Affiliation(s)
- Katsuhiro Kita
- Department of Biology, St. Francis College, Brooklyn, NY 11201, United States
| | - Allen Burdowski
- Department of Biology, St. Francis College, Brooklyn, NY 11201, United States
| |
Collapse
|
2
|
Descamps A, Arnoux P, Frochot C, Barbault F, Deschamp J, Monteil M, Migianu-Griffoni E, Legigan T, Lecouvey M. Synthesis and preliminary anticancer evaluation of photo-responsive prodrugs of hydroxymethylene bisphosphonate alendronate. Eur J Med Chem 2024; 269:116307. [PMID: 38460269 DOI: 10.1016/j.ejmech.2024.116307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/01/2024] [Accepted: 03/04/2024] [Indexed: 03/11/2024]
Abstract
The antitumoral activity of hydroxymethylene bisphosphonates (HMBP) such as alendronate or zoledronate is hampered by their exceptional bone-binding properties and their short plasmatic half-life which preclude their accumulation in non-skeletal tumors. In this context, the use of lipophilic prodrugs represents a simple and straightforward strategy to enhance the biodistribution of bisphosphonates in these tissues. We describe in this article the synthesis of light-responsive prodrugs of HMBP alendronate. These prodrugs include lipophilic photo-removable nitroveratryl groups which partially mask the highly polar alendronate HMBP scaffold. Photo-responsive prodrugs of alendronate are stable in physiological conditions and display reduced toxicity compared to alendronate against MDA-MB-231 cancer cells. However, the antiproliferative effect of these prodrugs is efficiently restored after cleavage of their nitroveratryl groups upon exposure to UV light. In addition, substitution of alendronate with such photo-responsive substituents drastically reduces its bone-binding properties, thereby potentially improving its biodistribution in soft tissues after i.v. administration. The development of such lipophilic photo-responsive prodrugs is a promising approach to fully exploit the anticancer effect of HMBPs on non-skeletal tumors.
Collapse
Affiliation(s)
- Aurélie Descamps
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | | | - Céline Frochot
- Université de Lorraine, CNRS, LRGP, F-54000, Nancy, France
| | | | - Julia Deschamp
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | - Maelle Monteil
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | - Evelyne Migianu-Griffoni
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | - Thibaut Legigan
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France.
| | - Marc Lecouvey
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France.
| |
Collapse
|
3
|
Lucchi R, Lucana MC, Escobar-Rosales M, Díaz-Perlas C, Oller-Salvia B. Site-specific antibody masking enables conditional activation with different stimuli. N Biotechnol 2023; 78:76-83. [PMID: 37820830 DOI: 10.1016/j.nbt.2023.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 09/17/2023] [Accepted: 10/07/2023] [Indexed: 10/13/2023]
Abstract
Antibody therapeutics show great potential to treat a variety of diseases. Often, the dose that can be safely administered is limited by side effects that arise from the interaction with the target outside the diseased tissue. Conditionally-active antibodies provide an additional layer of selectivity to improve safety. Distinct external stimuli or internal cues enable different control strategies and applications. However, current antibody masking strategies have low transferability across stimuli. Here we propose a versatile approach to conditionally mask antibody derivatives and its application to a single chain variable fragment (scFv) against a receptor expressed on cancer stem cells in several tumours. Our strategy relies on the site-specific conjugation of a polymer to an engineered cysteine residue through a chemically-synthesised linker that can be cleaved in response to the target stimulus. We show that the masking efficiency depends on the conjugation site and the size of the mask. An optimised mask decreases antigen binding by up to 20-fold and affinity can be fully recovered upon activation by exposure to light at 365 nm or by incubation with matrix metalloproteinases overexpressed in solid tumours. This approach opens up the possibility to rapidly engineer antibodies activatable with any internal or external stimulus.
Collapse
Affiliation(s)
- Roberta Lucchi
- Department of Bioengineering, Institut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain
| | - Maria C Lucana
- Department of Bioengineering, Institut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain
| | - Montserrat Escobar-Rosales
- Department of Bioengineering, Institut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain
| | - Cristina Díaz-Perlas
- Department of Bioengineering, Institut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain
| | - Benjamí Oller-Salvia
- Department of Bioengineering, Institut Químic de Sarrià (IQS), Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.
| |
Collapse
|
4
|
Brasino M, Wagnell E, Hamilton S, Ranganathan S, Gomes MM, Branchaud B, Messmer B, Ibsen SD. Turning antibodies off and on again using a covalently tethered blocking peptide. Commun Biol 2022; 5:1357. [PMID: 36496512 PMCID: PMC9741643 DOI: 10.1038/s42003-022-04094-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 10/11/2022] [Indexed: 12/13/2022] Open
Abstract
In their natural form, antibodies are always in an "on-state" and are capable of binding to their targets. This leads to undesirable interactions in a wide range of therapeutic, analytical, and synthetic applications. Modulating binding kinetics of antibodies to turn them from an "off-state" to an "on-state" with temporal and spatial control can address this. Here we demonstrate a method to modulate binding activity of antibodies in a predictable and reproducible way. We designed a blocking construct that uses both covalent and non-covalent interactions with the antibody. The construct consisted of a Protein L protein attached to a flexible linker ending in a blocking-peptide designed to interact with the antibody binding site. A mutant Protein L was developed to enable photo-triggered covalent crosslinking to the antibody at a specific location. The covalent bond anchored the linker and blocking peptide to the antibody light chain keeping the blocking peptide close to the antibody binding site. This effectively put the antibody into an "off-state". We demonstrate that protease-cleavable and photocleavable moieties in the tether enable controlled antibody activation to the "on-state" for anti-FLAG and cetuximab antibodies. Protein L can bind a range of antibodies used therapeutically and in research for wide applicability.
Collapse
Affiliation(s)
- Michael Brasino
- grid.5288.70000 0000 9758 5690Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201 USA
| | - Eli Wagnell
- grid.5288.70000 0000 9758 5690Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201 USA
| | - Sean Hamilton
- grid.5288.70000 0000 9758 5690Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201 USA ,grid.5288.70000 0000 9758 5690Department of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, OR 97201 USA
| | - Srivathsan Ranganathan
- grid.5288.70000 0000 9758 5690Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201 USA
| | - Michelle M. Gomes
- grid.5288.70000 0000 9758 5690Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201 USA
| | - Bruce Branchaud
- grid.5288.70000 0000 9758 5690Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201 USA
| | | | - Stuart D. Ibsen
- grid.5288.70000 0000 9758 5690Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201 USA ,grid.5288.70000 0000 9758 5690Department of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, OR 97201 USA
| |
Collapse
|
5
|
Tobiasz P, Borys F, Borecka M, Krawczyk H. Synthesis and Investigations of Building Blocks with Dibenzo[ b, f] Oxepine for Use in Photopharmacology. Int J Mol Sci 2021; 22:11033. [PMID: 34681697 PMCID: PMC8539288 DOI: 10.3390/ijms222011033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 09/30/2021] [Accepted: 10/05/2021] [Indexed: 01/18/2023] Open
Abstract
The synthesis of photoswitchable azo-dibenzo[b,f]oxepine derivatives and microtubule inhibitors were described. Subsequently, we examined the reaction of methoxy derivative 3-nitrodibenzo[b,f]oxepine with different aldehydes and in the presence of BF3·OEt2 as a catalyst. Our study provided a very concise method for the construction of the azo-dibenzo[b,f]oxepine skeleton. The analysis of products was run using experimental and theoretical methods. Next, we evaluated the E/Z isomerization of azo-dibenzo[b,f]oxepine derivatives, which could be photochemically controlled using visible-wavelength light.
Collapse
Affiliation(s)
- Piotr Tobiasz
- Department of Organic Chemistry, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland; (P.T.); (F.B.); (M.B.)
| | - Filip Borys
- Department of Organic Chemistry, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland; (P.T.); (F.B.); (M.B.)
- Laboratory of Cytoskeleton and Cilia Biology, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland
| | - Marta Borecka
- Department of Organic Chemistry, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland; (P.T.); (F.B.); (M.B.)
| | - Hanna Krawczyk
- Department of Organic Chemistry, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland; (P.T.); (F.B.); (M.B.)
| |
Collapse
|
6
|
Targeted Cancer Therapy Using Compounds Activated by Light. Cancers (Basel) 2021; 13:cancers13133237. [PMID: 34209493 PMCID: PMC8269035 DOI: 10.3390/cancers13133237] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 06/18/2021] [Accepted: 06/24/2021] [Indexed: 12/21/2022] Open
Abstract
Cancer chemotherapy is affected by a modest selectivity and toxic side effects of pharmacological interventions. Among novel approaches to overcome this limitation and to bring to therapy more potent and selective agents is the use of light for selective activation of anticancer compounds. In this review, we focus on the anticancer applications of two light-activated approaches still in the experimental phase: photoremovable protecting groups ("photocages") and photoswitches. We describe the structural considerations behind the development of novel compounds and the plethora of assays used to confirm whether the photochemical and pharmacological properties are meeting the stringent criteria for an efficient in vivo light-dependent activation. Despite its immense potential, light activation brings many challenges, and the complexity of the task is very demanding. Currently, we are still deeply in the phase of pharmacological tools, but the vivid research and rapid development bring the light of hope for potential clinical use.
Collapse
|
7
|
Arias-Alpizar G, Kong L, Vlieg RC, Rabe A, Papadopoulou P, Meijer MS, Bonnet S, Vogel S, van Noort J, Kros A, Campbell F. Light-triggered switching of liposome surface charge directs delivery of membrane impermeable payloads in vivo. Nat Commun 2020; 11:3638. [PMID: 32686667 PMCID: PMC7371701 DOI: 10.1038/s41467-020-17360-9] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Accepted: 06/25/2020] [Indexed: 01/14/2023] Open
Abstract
Surface charge plays a fundamental role in determining the fate of a nanoparticle, and any encapsulated contents, in vivo. Herein, we describe, and visualise in real time, light-triggered switching of liposome surface charge, from neutral to cationic, in situ and in vivo (embryonic zebrafish). Prior to light activation, intravenously administered liposomes, composed of just two lipid reagents, freely circulate and successfully evade innate immune cells present in the fish. Upon in situ irradiation and surface charge switching, however, liposomes rapidly adsorb to, and are taken up by, endothelial cells and/or are phagocytosed by blood resident macrophages. Coupling complete external control of nanoparticle targeting together with the intracellular delivery of encapsulated (and membrane impermeable) cargos, these compositionally simple liposomes are proof that advanced nanoparticle function in vivo does not require increased design complexity but rather a thorough understanding of the fundamental nano-bio interactions involved.
Collapse
Affiliation(s)
- Gabriela Arias-Alpizar
- Department o Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300, RA, Leiden, The Netherlands
| | - Li Kong
- Department o Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300, RA, Leiden, The Netherlands
- Tongji School of Pharmacy, Huazhong University of Science and Technology, 430030, Wuhan, P.R. China
| | - Redmar C Vlieg
- Leiden Institute of Physics (LION), Leiden University, P.O. Box 9504, 2300, RA, Leiden, The Netherlands
| | - Alexander Rabe
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, 5230, Odense, Denmark
- BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131, Mainz, Germany
| | - Panagiota Papadopoulou
- Department o Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300, RA, Leiden, The Netherlands
| | - Michael S Meijer
- Department of Metals in Catalysis, Biomimetics & Inorganic Materials (MCBIM), Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300, RA, Leiden, The Netherlands
| | - Sylvestre Bonnet
- Department of Metals in Catalysis, Biomimetics & Inorganic Materials (MCBIM), Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300, RA, Leiden, The Netherlands
| | - Stefan Vogel
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, 5230, Odense, Denmark
| | - John van Noort
- Leiden Institute of Physics (LION), Leiden University, P.O. Box 9504, 2300, RA, Leiden, The Netherlands
| | - Alexander Kros
- Department o Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300, RA, Leiden, The Netherlands.
| | - Frederick Campbell
- Department o Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300, RA, Leiden, The Netherlands.
| |
Collapse
|
8
|
Tamura R, Balabanova A, Frakes SA, Bargmann A, Grimm J, Koch TH, Yin H. Photoactivatable Prodrug of Doxazolidine Targeting Exosomes. J Med Chem 2019; 62:1959-1970. [PMID: 30703330 DOI: 10.1021/acs.jmedchem.8b01508] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Natural lipid nanocarriers, exosomes, carry cell-signaling materials such as DNA and RNA for intercellular communications. Exosomes derived from cancer cells contribute to the progression and metastasis of cancer cells by transferring oncogenic signaling molecules to neighboring and remote premetastatic sites. Therefore, applying the unique properties of exosomes for cancer therapy has been expected in science, medicine, and drug discovery fields. Herein, we report that an exosome-targeting prodrug system, designated MARCKS-ED-photodoxaz, could spatiotemporally control the activation of an exquisitely cytotoxic agent, doxazolidine (doxaz), with UV light. The MARCKS-ED peptide enters a cell by forming a complex with the exosomes in situ at its plasma membrane and in the media. MARCKS-ED-photodoxaz releases doxaz under near-UV irradiation to inhibit cell growth with low nanomolar IC50 values. The MARCKS-ED-photodoxaz system targeting exosomes and utilizing photochemistry will potentially provide a new approach for the treatment of cancer, especially for highly progressive and invasive metastatic cancers.
Collapse
Affiliation(s)
- Ryo Tamura
- Molecular Pharmacology Program , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | | | | | | | - Jan Grimm
- Molecular Pharmacology Program , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | | | - Hang Yin
- School of Pharmaceutical Sciences, Tsinghua University-Peking University Joint Center for Life Sciences , Tsinghua University , Beijing 100082 , China
| |
Collapse
|
9
|
Kong L, Poulcharidis D, Schneider GF, Campbell F, Kros A. Spatiotemporal Control of Doxorubicin Delivery from "Stealth-Like" Prodrug Micelles. Int J Mol Sci 2017; 18:E2033. [PMID: 28937592 PMCID: PMC5666715 DOI: 10.3390/ijms18102033] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2017] [Revised: 09/14/2017] [Accepted: 09/18/2017] [Indexed: 12/14/2022] Open
Abstract
In the treatment of cancer, targeting of anticancer drugs to the tumor microenvironment is highly desirable. Not only does this imply accurate tumor targeting but also minimal drug release en route to the tumor and maximal drug release once there. Here we describe high-loading, "stealth-like" doxorubicin micelles as a pro-drug delivery system, which upon light activation, leads to burst-like doxorbicin release. Through this approach, we show precise spatiotemporal control of doxorubicin delivery to cells in vitro.
Collapse
Affiliation(s)
- Li Kong
- Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
| | - Dimitrios Poulcharidis
- Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
| | - Gregory F Schneider
- Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
| | - Frederick Campbell
- Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
| | - Alexander Kros
- Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
| |
Collapse
|
10
|
Schutt C, Ibsen S, Zahavy E, Aryal S, Kuo S, Esener S, Berns M, Esener S. Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin. Pharm Res 2017; 34:2025-2035. [PMID: 28791550 DOI: 10.1007/s11095-017-2205-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Accepted: 06/08/2017] [Indexed: 12/20/2022]
Abstract
PURPOSE A major challenge facing nanoparticle-based delivery of chemotherapy agents is the natural and unavoidable accumulation of these particles in healthy tissue resulting in local toxicity and dose-limiting side effects. To address this issue, we have designed and characterized a new prodrug nanoparticle with controllable toxicity allowing a locally-delivered light trigger to convert the payload of the particle from a low to a high toxicity state. METHODS The nanoparticles are created entirely from light-activatable prodrug molecules using a nanoprecipitation process. The prodrug is a conjugate of doxorubicin and photocleavable biotin (DOX-PCB). RESULTS These DOX-PCB nanoparticles are 30 times less toxic to cells than doxorubicin, but can be activated to release pure therapeutic doxorubicin when exposed to 365 nm light. These nanoparticles have an average diameter of around 100 nm and achieve the maximum possible prodrug loading capacity since no support structure or coating is required to prevent loss of prodrug from the nanoparticle. CONCLUSIONS These light activatable nanoparticles demonstrate tunable toxicity and can be used to facilitate future therapy development whereby light delivered specifically to the tumor tissue would locally convert the nanoparticles to doxorubicin while leaving nanoparticles accumulated in healthy tissue in the less toxic prodrug form.
Collapse
Affiliation(s)
- Carolyn Schutt
- Department of Bioengineering, University of California San Diego, 9500 Gilman Dr. MC 0412, La Jolla, California, 92093-0412, USA.
| | - Stuart Ibsen
- Moores Cancer Center, University of California San Diego, La Jolla, California, 92093, USA
| | - Eran Zahavy
- Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, P.O. Box 19, 74100, Ness-Ziona, Israel
| | - Santosh Aryal
- Department of Chemistry, Nanotechnology Innovation Center of Kansas State, Kansas State University, Manhattan, Kansas, 66506, USA
| | - Stacey Kuo
- Department of Nanoengineering, University of California San Diego, La Jolla, California, 92093, USA
| | - Selin Esener
- Department of Nanoengineering, University of California San Diego, La Jolla, California, 92093, USA
| | - Michael Berns
- Department of Bioengineering, University of California San Diego, 9500 Gilman Dr. MC 0412, La Jolla, California, 92093-0412, USA
| | - Sadik Esener
- Department of Nanoengineering, University of California San Diego, La Jolla, California, 92093, USA
| |
Collapse
|
11
|
Perny M, Muri L, Dawson H, Kleinlogel S. Chronic activation of the D156A point mutant of Channelrhodopsin-2 signals apoptotic cell death: the good and the bad. Cell Death Dis 2016; 7:e2447. [PMID: 27809305 PMCID: PMC5260891 DOI: 10.1038/cddis.2016.351] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Revised: 09/09/2016] [Accepted: 09/26/2016] [Indexed: 12/24/2022]
Abstract
Channelrhodopsin-2 (ChR2) has become a celebrated research tool and is considered a promising potential therapeutic for neurological disorders. While making its way into the clinic, concerns about the safety of chronic ChR2 activation have emerged; in particular as the high-intensity blue light illumination needed for ChR2 activation may be phototoxic. Here we set out to quantify for the first time the cytotoxic effects of chronic ChR2 activation. We studied the safety of prolonged illumination on ChR2(D156A)-expressing human melanoma cells as cancer cells are notorious for their resistance to killing. Three days of illumination eradicated the entire ChR2(D156A)-expressing cell population through mitochondria-mediated apoptosis, whereas blue light activation of non-expressing control cells did not significantly compromise cell viability. In other words, chronic high-intensity blue light illumination alone is not phototoxic, but prolonged ChR2 activation induces mitochondria-mediated apoptosis. The results are alarming for gain-of-function translational neurological studies but open the possibility to optogenetically manipulate the viability of non-excitable cells, such as cancer cells. In a second set of experiments we therefore evaluated the feasibility to put melanoma cell proliferation and apoptosis under the control of light by transdermally illuminating in vivo melanoma xenografts expressing ChR2(D156A). We show clear proof of principle that light treatment inhibits and even reverses tumor growth, rendering ChR2s potential tools for targeted light-therapy of cancers.
Collapse
Affiliation(s)
- Michael Perny
- Institute for Physiology, University of Bern, Bern 3012 Switzerland
| | - Lukas Muri
- Institute for Physiology, University of Bern, Bern 3012 Switzerland
| | - Heather Dawson
- Institute of Pathology, Clinical Pathology Division, University of Bern, Bern 3010 Switzerland
| | - Sonja Kleinlogel
- Institute for Physiology, University of Bern, Bern 3012 Switzerland
| |
Collapse
|
12
|
Imstepf S, Pierroz V, Raposinho P, Bauwens M, Felber M, Fox T, Shapiro AB, Freudenberg R, Fernandes C, Gama S, Gasser G, Motthagy F, Santos IR, Alberto R. Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic Drug. Bioconjug Chem 2015; 26:2397-407. [PMID: 26473388 DOI: 10.1021/acs.bioconjchem.5b00466] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We present the combination of the clinically well-proven chemotherapeutic agent, Doxorubicin, and (99m)Tc, an Auger and internal conversion electron emitter, into a dual-action agent for therapy. Chemical conjugation of Doxorubicin to (99m)Tc afforded a construct which autonomously ferries a radioactive payload into the cell nucleus. At this site, damage is exerted by dose deposition from Auger radiation. The (99m)Tc-conjugate exhibited a dose-dependent inhibition of survival in a selected panel of cancer cells and an in vivo study in healthy mice evidenced a biodistribution which is comparable to that of the parent drug. The homologous Rhenium conjugate was found to effectively bind to DNA, inhibited human Topoisomerase II, and exhibited cytotoxicity in vitro. The collective in vitro and in vivo data demonstrate that the presented metallo-conjugates closely mimic native Doxorubicin.
Collapse
Affiliation(s)
| | | | - Paula Raposinho
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa , Estrada Nacional 10 km 139.7, PT-2695-066 Bobadela LRS, Portugal
| | - Matthias Bauwens
- Department of Nuclear Medicine, MUMC+ , P. Debeyelaan 25, NL-6229 Maastricht, Netherlands
| | | | | | - Adam B Shapiro
- Bioscience Department, Infection Innovative Medicines, AstraZeneca R&D Boston , Waltham, Massachusetts 02451, United States
| | - Robert Freudenberg
- Universitätsklinikum Carl Gustav Carus Dresden , Fetscherstrasse 74, D-01307 Dresden, Germany
| | - Célia Fernandes
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa , Estrada Nacional 10 km 139.7, PT-2695-066 Bobadela LRS, Portugal
| | - Sofia Gama
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa , Estrada Nacional 10 km 139.7, PT-2695-066 Bobadela LRS, Portugal
| | | | - Felix Motthagy
- Department of Nuclear Medicine, MUMC+ , P. Debeyelaan 25, NL-6229 Maastricht, Netherlands
| | - Isabel R Santos
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa , Estrada Nacional 10 km 139.7, PT-2695-066 Bobadela LRS, Portugal
| | | |
Collapse
|
13
|
Kress J, Rohrbach DJ, Carter KA, Luo D, Shao S, Lele S, Lovell JF, Sunar U. Quantitative imaging of light-triggered doxorubicin release. BIOMEDICAL OPTICS EXPRESS 2015; 6:3546-55. [PMID: 26417522 PMCID: PMC4574678 DOI: 10.1364/boe.6.003546] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Revised: 07/22/2015] [Accepted: 08/16/2015] [Indexed: 05/18/2023]
Abstract
The efficacy of chemotherapy is related, in large part, to the concentration of drug that reaches tumor sites. Doxorubicin (DOX) is a common anti-cancer drug that is also approved for use in liposomal form for the treatment of ovarian cancer. We recently developed a porphyrin-phospholipid (PoP)-liposome system that enables on demand release of DOX from liposomes using near infrared irradiation to improve DOX bioavailability. Owing to its intrinsic fluorescence, it is possible, and desirable, to quantify DOX concentration and distribution, preferably noninvasively. Here we quantified DOX distribution following light-triggered drug release in phantoms and an animal carcass using spatial frequency domain imaging. This study demonstrates the feasibility of non-invasive quantitative mapping of DOX distributions in target areas.
Collapse
Affiliation(s)
- Jeremy Kress
- Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA
- Department of Biomedical, Industrial & Human Factors Engineering, Wright State University, Dayton, OH, USA
| | - Daniel J. Rohrbach
- Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA
- Department of Biomedical, Industrial & Human Factors Engineering, Wright State University, Dayton, OH, USA
| | - Kevin A. Carter
- Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA
| | - Dandan Luo
- Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA
| | - Shuai Shao
- Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA
| | - Shashikant Lele
- Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - Jonathan F. Lovell
- Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA
| | - Ulas Sunar
- Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA
- Department of Biomedical, Industrial & Human Factors Engineering, Wright State University, Dayton, OH, USA
| |
Collapse
|
14
|
Borowiak M, Nahaboo W, Reynders M, Nekolla K, Jalinot P, Hasserodt J, Rehberg M, Delattre M, Zahler S, Vollmar A, Trauner D, Thorn-Seshold O. Photoswitchable Inhibitors of Microtubule Dynamics Optically Control Mitosis and Cell Death. Cell 2015; 162:403-411. [PMID: 26165941 DOI: 10.1016/j.cell.2015.06.049] [Citation(s) in RCA: 282] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Revised: 03/06/2015] [Accepted: 06/12/2015] [Indexed: 01/22/2023]
Abstract
Small molecules that interfere with microtubule dynamics, such as Taxol and the Vinca alkaloids, are widely used in cell biology research and as clinical anticancer drugs. However, their activity cannot be restricted to specific target cells, which also causes severe side effects in chemotherapy. Here, we introduce the photostatins, inhibitors that can be switched on and off in vivo by visible light, to optically control microtubule dynamics. Photostatins modulate microtubule dynamics with a subsecond response time and control mitosis in living organisms with single-cell spatial precision. In longer-term applications in cell culture, photostatins are up to 250 times more cytotoxic when switched on with blue light than when kept in the dark. Therefore, photostatins are both valuable tools for cell biology, and are promising as a new class of precision chemotherapeutics whose toxicity may be spatiotemporally constrained using light.
Collapse
Affiliation(s)
- Malgorzata Borowiak
- Department of Chemistry and Pharmacy and Centre for Integrated Protein Science, Ludwig-Maximilians-University Munich, 5-13 Butenandtstrasse, 81377 Munich, Germany; Laboratoire de Biologie Moléculaire de la Cellule, CNRS, École Normale Supérieure de Lyon, 46 Allée d'Italie, 69364 Lyon, France
| | - Wallis Nahaboo
- Laboratoire de Biologie Moléculaire de la Cellule, CNRS, École Normale Supérieure de Lyon, 46 Allée d'Italie, 69364 Lyon, France
| | - Martin Reynders
- Department of Chemistry and Pharmacy and Centre for Integrated Protein Science, Ludwig-Maximilians-University Munich, 5-13 Butenandtstrasse, 81377 Munich, Germany
| | - Katharina Nekolla
- Walter Brendel Centre of Experimental Medicine, 27 Marchioninistrasse, Ludwig-Maximilians-Universität, München, Munich 81377, Germany
| | - Pierre Jalinot
- Laboratoire de Biologie Moléculaire de la Cellule, CNRS, École Normale Supérieure de Lyon, 46 Allée d'Italie, 69364 Lyon, France
| | - Jens Hasserodt
- Laboratoire de Chimie, CNRS, École Normale Supérieure de Lyon, 46 Allée d'Italie, 69364 Lyon, France
| | - Markus Rehberg
- Walter Brendel Centre of Experimental Medicine, 27 Marchioninistrasse, Ludwig-Maximilians-Universität, München, Munich 81377, Germany
| | - Marie Delattre
- Laboratoire de Biologie Moléculaire de la Cellule, CNRS, École Normale Supérieure de Lyon, 46 Allée d'Italie, 69364 Lyon, France
| | - Stefan Zahler
- Department of Chemistry and Pharmacy and Centre for Integrated Protein Science, Ludwig-Maximilians-University Munich, 5-13 Butenandtstrasse, 81377 Munich, Germany
| | - Angelika Vollmar
- Department of Chemistry and Pharmacy and Centre for Integrated Protein Science, Ludwig-Maximilians-University Munich, 5-13 Butenandtstrasse, 81377 Munich, Germany
| | - Dirk Trauner
- Department of Chemistry and Pharmacy and Centre for Integrated Protein Science, Ludwig-Maximilians-University Munich, 5-13 Butenandtstrasse, 81377 Munich, Germany.
| | - Oliver Thorn-Seshold
- Department of Chemistry and Pharmacy and Centre for Integrated Protein Science, Ludwig-Maximilians-University Munich, 5-13 Butenandtstrasse, 81377 Munich, Germany; Laboratoire de Chimie, CNRS, École Normale Supérieure de Lyon, 46 Allée d'Italie, 69364 Lyon, France.
| |
Collapse
|
15
|
Girotti AW, Minotti G. Development of a tumor-specific photoactivatable doxorubicin prodrug. Photochem Photobiol 2013; 89:1009-10. [PMID: 23944612 DOI: 10.1111/php.12151] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2013] [Accepted: 08/02/2013] [Indexed: 01/15/2023]
Abstract
This is a retrospective highlight on the publication by Ibsen and coworkers: Localized In Vivo Activation of a Photoactivatable Doxorubicin Prodrug in Deep Tumor Tissue, which appeared in a preceding issue of Photochem. Photobiol. (2013, 89:698-708). The authors describe the synthesis and properties of a novel doxorubicin (DOX) prodrug, DOX-PCB, which contains a photocleavable linker group. Systemic administration of the prodrug to a tumor-bearing animal followed by LED/fiber optic 365 nm light delivery allowed active DOX to be released site specifically in the tumor area. This elegant and timely study provides compelling evidence that photocleavable DOX-PCB can eliminate many of the toxic side effects of DOX that have plagued clinical use of this highly effective antitumor drug for many years.
Collapse
Affiliation(s)
- Albert W Girotti
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI
| | | |
Collapse
|
16
|
Ibsen S, Su Y, Norton J, Zahavy E, Hayashi T, Adams S, Wrasidlo W, Esener S. Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue. JOURNAL OF MASS SPECTROMETRY : JMS 2013; 48:768-73. [PMID: 23832932 PMCID: PMC4110111 DOI: 10.1002/jms.3221] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Revised: 02/26/2013] [Accepted: 04/10/2013] [Indexed: 05/15/2023]
Abstract
The localized conversion of inactive doxorubicin prodrug chemotherapeutics to pharmacalogically active forms is difficult to quantify in mouse tumor models because it occurs only in small regions of tissue. The tumor tissue extraction protocol and LC-MS/MS analysis method described here were optimized to obtain a detection limit of 7.8 pg for the activated doxorubicin and 0.36 ng for the doxorubicin prodrug. This method can be useful for determining the biodistribution and activation efficiency for many different doxorubicin prodrugs. It can also be used for quantification of doxorubicin from tumor models that have poor vascularization resulting in low tissue accumulation.
Collapse
Affiliation(s)
- Stuart Ibsen
- Department of Bioengineering, Moores Cancer Center, University of California San Diego, 3855 Health Sciences Dr. # 0815, La Jolla, CA 92093-0815, USA.
| | | | | | | | | | | | | | | |
Collapse
|